ApeX Therapeutics Names Steve Carchedi President and CEO

Cancer drug developer ApeX Therapeutics has appointed Steve Carchedi president and CEO of the Indianapolis, IN-based company. He succeeds David Broecker, who will continue to serve on the company’s board of directors.

Carchedi comes to ApeX from Cranbury, NJ-based Cornerstone Pharmaceuticals. His experience also includes various roles at Covidien, Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), Eli Lilly (NYSE: [[ticker:LLY]]), and Johnson and Johnson (NYSE: [[ticker:JNJ]]). ApeX says its lead drug candidate, APX3330, targets a protein found in many cancers.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan